DexCom, Inc. (DXCM)
NASDAQ · Healthcare · Medical - Devices
Profile
DexCom, Inc.
- Exchange
- NASDAQ
- Ticker
- DXCM
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- US
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Key facts
DexCom, Inc.: key facts
- DexCom, Inc. (NASDAQ: DXCM) is a Medical - Devices company in the Healthcare sector.
- In fiscal 2025, DexCom, Inc. reported revenue of $4.7B and net income of $836.3M.
- Revenue grew 17.5% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $5.1B and net income was $991.0M.
MonkScore
DexCom, Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 3 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability90–100
- Quality70–80
- Market Conviction70–80
- Safety90–100
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
DexCom, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $5.1B | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B |
| Gross profit | $3.2B | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B |
| Operating income | $1.2B | $911.8M | $600.0M | $597.7M | $391.2M | $265.8M |
| Net income | $991.0M | $836.3M | $576.2M | $541.5M | $341.2M | $216.9M |
| Operating cash flow | $1.4B | $1.4B | $989.5M | $748.5M | $669.5M | $442.5M |
| Capital expenditure | -$316.1M | -$363.5M | -$358.8M | -$236.6M | -$364.8M | -$389.2M |
| Free cash flow | $1.1B | $1.1B | $630.7M | $511.9M | $304.7M | $53.3M |
| Total debt | $1.4B | $1.4B | $2.6B | $2.6B | $2.1B | $2.2B |
| Cash | $961.4M | $917.7M | $606.1M | $566.3M | $642.3M | $1.1B |
Revenue growth a year
- 1-year
- 15.6%
- 3-year
- 17.0%
- 4-year
- 17.5%
Compound growth between fiscal years.
Peers
Similar companies
- Insulet Corp.NASDAQ:PODDMonkScore range: 90–100
- Bioventus Inc.NASDAQ:BVSMonkScore range: 90–100
- IRadimed CorporationNASDAQ:IRMDMonkScore range: 90–100
- Alphatec Holdings, Inc.NASDAQ:ATECMonkScore range: 90–100
- Glaukos CorporationNYSE:GKOSMonkScore range: 90–100
- Delcath Systems, Inc.NASDAQ:DCTHMonkScore range: 80–90
- Penumbra, Inc.NYSE:PENMonkScore range: 80–90
- Cerus CorporationNASDAQ:CERSMonkScore range: 80–90
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.